Biopharmaceutical company GSK plc (LSE/NYSE:GSK) announced on Tuesday that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational B7-H3-targeted antibody-drug conjugate (ADC), GSK5764227 (GSK'227), for the treatment of relapsed or refractory extensive-stage small-cell lung cancer (ES-SCLC).
This designation is based on promising early clinical data demonstrating the potential of GSK'227 to significantly improve outcomes for patients with this aggressive and difficult-to-treat cancer.
GSK acquired global rights to GSK'227 from Hansoh Pharma (HKG:3692) earlier this year. The company plans to initiate global phase 1/2 trials in the second half of 2024 to support a registrational pathway for GSK'227.
Breakthrough Therapy Designation aims to expedite the development and review of drugs with the potential to offer an improvement over available therapies for serious conditions.
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Dupixent receives approval in Japan as first biologic for COPD treatment
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Actinium Pharmaceuticals signs Ac-225 radioisotope agreement with Eckert & Ziegler
GSK's Nucala (Mepolizumab) COPD application accepted by EMA
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment
Altesa BioSciences granted US regulatory approval for vapendavir clinical trials
Black Diamond Therapeutics and Servier agree global licensing deal for BDTX-4933
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer